Fathom Therapeutics Raises $47 Million to Advance AI Drug Design Platform

Apr 28, 2026
Fathom Therapeutics, formerly Atommap Corp., has secured $47 million in an oversubscribed Series A round led by Sutter Hill Ventures. The company uses quantum chemistry and AI through its Microcosmos platform to design small molecule drugs and will use the funds to expand lab and discovery programs.

Fathom Therapeutics, formerly Atommap Corp., has raised $47 million in an oversubscribed Series A financing led by Sutter Hill Ventures, announced in a press release.

The company applies quantum chemistry and artificial intelligence to design small molecule drugs. Its Microcosmos platform simulates protein dynamics to identify molecules with therapeutic potential.

Funding from the Series A round will be used to strengthen laboratory capabilities and expand discovery programs. Fathom has also appointed Mandana Honu as Chief Business Officer and added Diala Ezzeddine to its board of directors.

We hope you enjoyed this article

Free newsletter

AI Funding Brief

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.